ATE381624T1 - Retrovirale vektoren mit verminderter rekombinationsrate - Google Patents

Retrovirale vektoren mit verminderter rekombinationsrate

Info

Publication number
ATE381624T1
ATE381624T1 AT95920386T AT95920386T ATE381624T1 AT E381624 T1 ATE381624 T1 AT E381624T1 AT 95920386 T AT95920386 T AT 95920386T AT 95920386 T AT95920386 T AT 95920386T AT E381624 T1 ATE381624 T1 AT E381624T1
Authority
AT
Austria
Prior art keywords
pol
gag
expression cassettes
env
ltr
Prior art date
Application number
AT95920386T
Other languages
English (en)
Inventor
James G Respess
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE381624T1 publication Critical patent/ATE381624T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
AT95920386T 1994-05-09 1995-05-09 Retrovirale vektoren mit verminderter rekombinationsrate ATE381624T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24003094A 1994-05-09 1994-05-09

Publications (1)

Publication Number Publication Date
ATE381624T1 true ATE381624T1 (de) 2008-01-15

Family

ID=22904813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920386T ATE381624T1 (de) 1994-05-09 1995-05-09 Retrovirale vektoren mit verminderter rekombinationsrate

Country Status (8)

Country Link
EP (2) EP1881075B1 (de)
JP (1) JP4303315B2 (de)
AT (1) ATE381624T1 (de)
AU (1) AU2585395A (de)
CA (1) CA2158977A1 (de)
DE (1) DE69535669T2 (de)
ES (1) ES2297831T3 (de)
WO (1) WO1995030763A2 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
CN1263867C (zh) * 1996-01-29 2006-07-12 病毒科学公司 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法
WO1997035996A1 (en) * 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
EP0906441A1 (de) * 1996-03-25 1999-04-07 Transgene S.A. Antitumorzellzusammensetzungen, die auf mindestens drei transgene exprimieren
DE69739286D1 (de) * 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
KR100246096B1 (ko) 1996-09-21 2000-03-15 이선경 유전자 요법을 위한 개선된 레트로바이러스 벡터
WO1999020311A1 (en) * 1997-10-21 1999-04-29 Chiron Corporation METHODS FOR CANCER IMMUNOTHERAPY USING RETROVIRAL VECTORS EXPRESSING η INTERFERON
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
WO1999025862A2 (en) * 1997-11-19 1999-05-27 Nature Technology, Inc. Chimeric viral packaging signal without gag gene sequences
CN1322137C (zh) * 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
GB2334257B (en) * 1997-12-22 2001-07-04 Oxford Biomedica Ltd Rectroviral vectors
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
EP2261343A3 (de) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
EP1232264B1 (de) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Menschliches fgf-21 gen und genexpressionsprodukte
BRPI0107679B8 (pt) 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
EP1854476A3 (de) 2000-02-09 2008-05-07 Bas Medical, Inc. Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2305087T3 (es) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
KR100440852B1 (ko) * 2001-05-10 2004-07-19 주식회사 바이로메드 레트로바이러스에 특이적인 올리고뉴클레오티드 프라이머및 이를 이용한 레트로바이러스 농도 측정방법
ATE466020T1 (de) 2001-11-09 2010-05-15 Univ Georgetown Neue isoform des gefässendothelzell wachstumshemmers (vegi)
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
EP1501855A4 (de) 2002-03-21 2006-02-22 Sagres Discovery Inc Neue zusammensetzungen und verfahren bei krebs
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP2302039A1 (de) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virusähnliche Partikel mit HML-2 gag Polypeptid
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP2279746B1 (de) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Oberflächenproteine in neisseria meningitidis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ATE553128T1 (de) 2002-12-24 2012-04-15 Rinat Neuroscience Corp Anti-ngf-antikörper und verfahren zu ihrer verwendung
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
PL379983A1 (pl) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EA200601220A1 (ru) 2003-12-23 2006-12-29 Ринат Ньюросайенс Корп. Анти-trkc антитела-агонисты и способы их применения
JP2007526774A (ja) * 2004-03-01 2007-09-20 ピーター・マッカラム・キャンサー・インスティテュート 組換えパーフォリン、その発現、およびその使用
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP3381930A1 (de) 2004-07-09 2018-10-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche formen von hendra- und nipah-virus-g-glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
AU2006235258A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
HUE036940T2 (hu) 2005-11-14 2018-08-28 Teva Pharmaceuticals Int Gmbh Kalcitonin gén-rokon peptid ellen irányuló antagonista ellenanyag
WO2007146172A2 (en) 2006-06-07 2007-12-21 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2008337100B2 (en) 2007-12-17 2013-02-28 Pfizer Limited Treatment of interstitial cystitis
BRPI0820452A2 (pt) 2007-12-18 2015-06-16 Bioalliance Cv Anticorpos que reconhecendo um epítopo contendo um carboidrato em cd-43 e cea expressos em células cancerosas e métodos de uso dos mesmos.
CA2718975A1 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2419129A2 (de) 2009-04-14 2012-02-22 Novartis AG Zusammensetzungen zur immunisierung gegen staphylococcus aerus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2464658B1 (de) 2009-07-16 2014-10-01 Novartis AG Detoxifizierte escherichia coli immunogene
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP2598126A2 (de) 2010-07-30 2013-06-05 Saint Louis University Verfahren zur behandlung von schmerz
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2698635A3 (de) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Verfahren und Zusammensetzungen zum Targeting auf Stellen neovaskulären Wachstums
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CA2859472A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2014008263A2 (en) 2012-07-02 2014-01-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus and methods of use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
JP2015536339A (ja) 2012-11-09 2015-12-21 ファイザー・インク 血小板由来増殖因子ｂ特異的抗体ならびにこれらの組成物および使用
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
PE20151871A1 (es) 2013-05-07 2015-12-24 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN113683695A (zh) 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
EP3068801A1 (de) 2013-11-13 2016-09-21 Pfizer Inc. Tumornekrosefaktorähnliche ligand-1a-spezifische antikörper sowie zusammensetzungen damit und verwendungen davon
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EA201691787A1 (ru) 2014-03-21 2017-02-28 Тева Фармасьютикалз Интернэшнл Гмбх Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
JP6894236B2 (ja) 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
CA2925329C (en) 2015-04-13 2024-01-02 Pfizer Inc. Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
CA3036652A1 (en) 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
EP3478325A4 (de) 2016-07-01 2020-01-15 Research Development Foundation Eliminierung von proliferierenden zellen aus stammzellbasierten transplantaten
JP2020510435A (ja) 2017-03-03 2020-04-09 ライナット ニューロサイエンス コーポレイション 抗ｇｉｔｒ抗体およびその使用方法
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
PE20191846A1 (es) 2017-06-02 2019-12-31 Pfizer Anticuerpos especificos para flt3 y sus usos
DE112018002990T5 (de) 2017-06-13 2020-04-02 Bostongene Corporation Systeme und verfahren zum erzeugen, visualisieren und klassifizieren von molekularen funktionellen profilen
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
JP2020536115A (ja) 2017-10-04 2020-12-10 オプコ ファーマシューティカルズ、エルエルシー 癌の個別化療法に関する物品および方法
US11396551B2 (en) 2018-02-01 2022-07-26 Pfizer Inc. Chimeric antigen receptors targeting CD70
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
RU2020128440A (ru) 2018-02-28 2022-03-28 Пфайзер Инк. Варианты il-15 и их применения
TWI816396B (zh) 2018-05-23 2023-09-21 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
JP7384835B2 (ja) 2018-05-23 2023-11-21 ファイザー・インク Ｃｄ３に特異的な抗体及びその使用
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
EP4146688A1 (de) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Maskenpeptide und maskierte anti-ptk7-antikörper damit
PE20231565A1 (es) 2020-07-17 2023-10-04 Pfizer Anticuerpos terapeuticos y sus usos
WO2022023972A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
WO2022120256A2 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022232615A1 (en) 2021-04-29 2022-11-03 Bostongene Corporation Machine learning techniques for estimating tumor cell expression complex tumor tissue
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (de) 1983-07-25 1985-02-13 Mgi Pharma, Inc. Papillomavirus-Immunogene
DE3583564D1 (de) 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
US4939088A (en) 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
JP2694228B2 (ja) 1987-11-12 1997-12-24 壹夫 柳 抗ｅｂｎａ抗体の測定法
CA1315719C (en) * 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
DE68926859T2 (de) 1988-11-10 1997-02-13 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
CA2005311C (en) 1988-12-13 2006-05-30 Edward A. Hoover Prototype felv isolates for use in disease models and vaccines
EP0454781B1 (de) 1989-01-23 1998-12-16 Chiron Corporation Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
EP0860504A1 (de) 1989-05-08 1998-08-26 Idexx Laboratories, Inc. Polypeptide des T-Zell spezifischen lymphotropen Lentivirus aus Katze
ATE368112T1 (de) 1989-12-22 2007-08-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
AU8762991A (en) 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DK0568537T3 (da) * 1990-10-31 1998-09-23 Whitehead Biomedical Inst Genetisk modificering af endotelceller
US6228608B1 (en) 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5226600A (en) 1991-08-02 1993-07-13 Wagner Spray Tech Corporation Check valve
FR2683226B1 (fr) 1991-10-30 1995-06-09 Univ Paris Curie Cellules piegees a l'egard d'antigenes provoquant le dysfonctionnement du systeme immunitaire, medicaments pour la prevention ou le traitement de maladies induites par ces dysfonctionnements.
ES2142834T3 (es) 1991-10-30 2000-05-01 Univ Paris Curie Celulas transformadas para la prevencion o el tratamiento de enfermedades inducidas por virus, en particular retrovirus patogenos.
GB9123377D0 (en) 1991-11-02 1991-12-18 Epro Uk Ltd Coating of surface with bitumen membrane
EP0611397B1 (de) 1991-11-08 2002-06-19 PHARMACIA & UPJOHN COMPANY Vakzine gegen katzenleukämievirus
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
CA2117303C (en) 1991-11-29 2000-10-17 Sunil Chada Anti-cancer immunotherapeutic vector constructs
PT625204E (pt) 1992-02-04 2002-10-31 Chiron Corp Terapeutica da hepatite
JPH07508179A (ja) 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US5306800A (en) 1992-11-09 1994-04-26 Hoechst Celanese Corp. Pseudo network condensation polymers
EP0673253A1 (de) 1992-12-11 1995-09-27 NanoSystems L.L.C. Zusammensetzung gegen übersäuerung und methode zur herstellung
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
JP4126085B2 (ja) 2002-03-15 2008-07-30 富士通株式会社 表示同期方法および表示同期装置
RU2237743C2 (ru) 2002-09-26 2004-10-10 Закрытое акционерное общество "Межотраслевое юридическое агентство "Юрпромконсалтинг" Способ обработки поверхности протяженного изделия, линия и устройство для его осуществления
JP4625724B2 (ja) 2005-06-28 2011-02-02 株式会社ホンダロック 車両盗難防止装置
NZ563431A (en) 2005-06-30 2012-05-25 Biocrates Life Sciences Ag Device for quantitative analysis of a metabolite profile
KR100790837B1 (ko) 2007-04-30 2008-01-03 삼성전자주식회사 휴대용 단말기에서 전류 소모 제어 장치 및 방법
TWI456969B (zh) 2007-08-24 2014-10-11 Htc Corp 可攜式電子裝置
US7965084B2 (en) 2008-04-21 2011-06-21 Formfactor, Inc. Self-monitoring switch
ES2368952T3 (es) 2008-05-27 2011-11-23 Abb Schweiz Ag Dispositivo de arranque para al menos dos máquinas sincrónicas.
US8032846B1 (en) 2010-03-30 2011-10-04 Synopsys, Inc. Efficient provisioning of resources in public infrastructure for electronic design automation (EDA) tasks

Also Published As

Publication number Publication date
WO1995030763A3 (en) 1996-04-04
AU2585395A (en) 1995-11-29
EP0772689A2 (de) 1997-05-14
EP1881075B1 (de) 2013-07-24
DE69535669D1 (de) 2008-01-31
JPH10500287A (ja) 1998-01-13
WO1995030763A2 (en) 1995-11-16
DE69535669T2 (de) 2008-12-04
CA2158977A1 (en) 1995-11-10
JP4303315B2 (ja) 2009-07-29
EP0772689B1 (de) 2007-12-19
ES2297831T3 (es) 2008-05-01
EP1881075A1 (de) 2008-01-23

Similar Documents

Publication Publication Date Title
DE69535669D1 (de) Retrovirale vektoren mit verminderter rekombinationsrate
ATE424463T1 (de) Rekombinationsunfähige retrovirale vektoren
GB2369121A (en) Producer cell for the production of retroviral vectors
GB2331522A (en) Lentiviral vectors
GB2164256B (en) Toothpaste compositions
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
ITMI912457A1 (it) Policarbonati dioloterminati
IT1252388B (it) Polimeri e copolimeri del propilene aggraffati con vinilpolibutadiene e procedimento di preparazione
ITMI931963A1 (it) Procedimento per la preparazione di copolimeri elastomerici dell'etilene e prodotti ottenuti
EP0816487A4 (de) Zelle, die rekombinanten hiv produziert
WO1996007749A3 (en) Methods and compositions for inhibiting production of replication competent virus
DE69405230D1 (de) Prostaglandinrezeptor ep1 kodierende dna
DE50113794D1 (de) Verwendung von polysäuren mit enger molmassenverteilung
GB1525580A (en) Photocrosslinkable compositions
DK0817860T3 (da) Pseudotype retrovirale partikler
NO20002013D0 (no) Suspensjonsforpakningscellelinjer for retrovirusvektorer
AR020076A1 (es) LíNEA CELULAR DE EMPAQUETAMIENTO DE RETROVIRUS ANFOTRoPICO, PROCESO PARA SU PRODUCCIoN, Y PROCESO PARA LA PRODUCCIoN DE UN VECTOR RETROVIRAL MEDIANTE LA MISMA.
DE69215148D1 (de) Dithiansubstituierte Propenale und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0772689

Country of ref document: EP